Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLO‐C): An open‐label, single‐arm, phase 4, multicentre trial

BACKGROUND AND AIMS: Direct‐acting antiviral therapy for hepatitis C virus (HCV) is effective, but few prospective studies among people with ongoing injecting drug use exist. This study evaluated the efficacy of elbasvir/grazoprevir in people with HCV genotype 1/4 (G1/4) infection and recent injecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Grebely, Jason, Read, Phillip, Cunningham, Evan B., Weltman, Martin, Matthews, Gail V., Dunlop, Adrian, Montebello, Mark, Martinello, Marianne, Gilliver, Rosie, Marks, Philippa, Applegate, Tanya L., Dore, Gregory J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136479/
https://www.ncbi.nlm.nih.gov/pubmed/32270056
http://dx.doi.org/10.1002/hsr2.151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136479/
https://www.ncbi.nlm.nih.gov/pubmed/32270056
http://dx.doi.org/10.1002/hsr2.151

Ejemplares similares